A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
United States
Barrow Neurological Institute, Phoenix, Arizona Indiana University / IU Health, Indianapolis, Indiana University of Kansas Medical Center Research Institute, Fairway, Kansas Massachusetts General Hospital, Boston, Massachusetts The Washington University, St Louis, Missouri Last updated December 2025